Cargando…
RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM)
BACKGROUND: NRG CC001, a phase III trial of WBRT+memantine (WBRT+M) with or without Hippocampal Avoidance (HA), sought to assess the neuro-protective effects of lowering the radiation dose received by the hippocampus. METHODS: Patients (pts) with brain metastases were stratified by RPA class and pri...
Autores principales: | Tomé, Wolfgang, Deshmukh, Snehal, Gondi, Vinai, Brown, Paul, Wefel, Jeffery, Armstrong, Terri, Bruner, Deborah, Bovi, Joseph, Robinson, Clifford, Khuntia, Deepak, Grosshans, David, Konski, Andre, Roberge, David, Kundapur, Vijayananda, Devisetty, Kiran, Shah, Sunjay, Usuki, Kenneth, Anderson, Bethany Marie, Mehta, Minesh, Kachnic, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213360/ http://dx.doi.org/10.1093/noajnl/vdz014.104 |
Ejemplares similares
-
RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
por: Bovi, Joseph, et al.
Publicado: (2019) -
Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933
por: Abraham, Christopher D., et al.
Publicado: (2021) -
Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
por: Bovi, Joseph A., et al.
Publicado: (2019) -
RADI-01. PROGNOSTIC FACTORS OF SHORT SURVIVAL FOR BRAIN METASTASES TREATED WITH SRS WITHOUT WBRT.
por: Harat, Maciej, et al.
Publicado: (2019) -
RADI-16. Efficacy of WBRT among the Sub-types of Metastatic Breast Cancer
por: Mathew, Shija, et al.
Publicado: (2021)